CareDx, Inc

CareDx, Inc Earnings Recaps

CDNA Health Care 2 recaps
Q1 2026 Apr 29, 2026

Shares of CareDx, Inc declined 4.8% post-earnings as investors reacted negatively to a more cautious outlook and slower momentum in key business drivers. Management's revised strategy update and portfolio shifts did not fully allay concerns about deceleration in core growth metrics.

Key takeaways
  • The company announced the divestiture of its Lab Products business and an acquisition of Navaris, signaling a pivot in portfolio priorities.
  • Management emphasized ongoing pipeline progress, including the upcoming AlloSure liver program and the planned launch of HistoMap kidney, but specifics on adoption or revenue contribution were limited.
  • Workflow integration remains a focus, with a target of 50% of testing volume through Epic-integrated sites by year-end; progress was noted, but ultimate impact remains to be demonstrated.
  • Clinical adoption outside core kidney testing (notably HeartCare and lung indications) was discussed, but updates suggested incremental rather than breakout momentum.
  • The updated 2026 outlook was highlighted on the call, but the market's negative reaction suggests investors remain concerned about growth trajectory and the impact of strategic repositioning.
Full recap
Q3 2025 Nov 5, 2025

CareDx reported robust third-quarter 2025 results with total revenue reaching $100.1 million, marking a 21% year-over-year growth, driven by strong performance across its testing services and product offerings.

Key takeaways
  • Testing Services revenue reached $72.2 million, a 19% increase year-over-year, with a total of approximately 50,300 tests delivered.
  • Adjusted EBITDA surged to $15.3 million, more than doubling from the same quarter last year.
  • The company has raised its 2025 revenue guidance to $372-$376 million and adjusted EBITDA guidance to $35-$39 million.
  • CareDx announced the launch of HistoMap Kidney, a breakthrough tissue-based molecular test aimed at improving diagnostic precision in transplant care.
  • Share repurchases accelerated, with 2 million shares bought back at an average price of $12.87, totaling approximately 9% repurchased year-to-date.
Full recap